CytoDyn (CYDY) Stock Price, News & Analysis

Company Overview

CytoDyn Inc. is a biotechnology company focused on developing innovative therapeutics for diseases associated with the CCR5 receptor, a protein involved in immune-cell signaling and the progression of certain cancers and inflammatory conditions. The company is headquartered in Vancouver, Washington.

CytoDyn’s lead investigational product is leronlimab, also known as PRO 140, a monoclonal antibody designed to block CCR5. The company has studied leronlimab in several potential applications, including HIV infection, cancer and inflammatory diseases. Leronlimab remains an investigational therapy and is not approved for commercial use by the U.S. Food and Drug Administration.

Historically, CytoDyn conducted clinical development programs involving HIV and COVID-19, while more recent efforts have emphasized oncology applications, including metastatic colorectal cancer and triple-negative breast cancer. The company’s research and regulatory activities have primarily centered on the United States, and its development programs may change as clinical and regulatory evaluations progress.

Key Stats

• Today's Range: $0.22 to $0.24
• 50-Day Range: $0.19 to $0.26
• 52-Week Range: $0.18 to $0.40
• Volume: 1.73 million shs
• Average Volume: 2.56 million shs
• Market Capitalization: $344.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CytoDyn Stock Analysis - MarketRank™

CytoDyn scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CytoDyn.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CytoDyn is -7.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CytoDyn is -7.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.41% of the float of CytoDyn has been sold short.

Short Interest Ratio / Days to Cover

CytoDyn has a short interest ratio ("days to cover") of 15.16, which indicates bearish sentiment.

Change versus previous month

Short interest in CytoDyn has recently decreased by 0.01%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoDyn does not currently pay a dividend.

Dividend Growth

CytoDyn does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

CytoDyn has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

Search Interest

2 people have searched for CYDY on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added CytoDyn to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytoDyn insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of CytoDyn is held by insiders.

Percentage Held by Institutions

5.06% of the stock of CytoDyn is held by institutions.

Company Calendar

• Last Earnings: 10/14/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 1/14/2027
• Fiscal Year End: 5/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CYDY
• Previous Symbol: NASDAQ:CYDY
• CIK: 1175680
• Web: www.cytodyn.com
• Phone: (360) 980-8524
• Fax: N/A
• Employees: 14
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -268.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.08) per share
• Price / Book: -2.83

Miscellaneous

• Outstanding Shares: 1,523,140,000
• Free Float: 1,507,906,000
• Market Cap: $344.69 million
• Optionable: Not Optionable
• Beta: 1.71